Altimmune
ALT
182 hedge funds and large institutions have $292M invested in Altimmune in 2024 Q4 according to their latest regulatory filings, with 38 funds opening new positions, 65 increasing their positions, 44 reducing their positions, and 23 closing their positions.
65% more first-time investments, than exits
New positions opened: 38 | Existing positions closed: 23
48% more repeat investments, than reductions
Existing positions increased: 65 | Existing positions reduced: 44
43% more call options, than puts
Call options by funds: $23M | Put options by funds: $16.1M
20% more capital invested
Capital invested by funds: $243M → $292M (+$48.9M)
8% more funds holding
Funds holding: 169 → 182 (+13)
1.27% more ownership
Funds ownership: 55.64% → 56.91% (+1.3%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Ameriprise
Minneapolis,
Minnesota
|
+$10.5M |
| 2 |
BlackRock
New York
|
+$5.3M |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$3.34M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$1.89M |
| 5 |
Millennium Management
New York
|
+$1.84M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital Fund Management (CFM)
Paris,
France
|
-$4.46M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$4.22M |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$3.25M |
| 4 |
Goldman Sachs
New York
|
-$3.11M |
| 5 |
Morgan Stanley
New York
|
-$2.86M |
ALT Hedge Fund Activity: Q4 2024 in Review
182 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Altimmune (ALT) for Q4 2024, worth a combined $292M — up 20% from $243M a quarter earlier.
Buyers outnumbered sellers: 38 funds opened new ALT positions and 23 closed out — a net gain of 15 holders — while 65 added to existing stakes and 44 trimmed.
The largest buyer was Ameriprise, adding an estimated $10.5M. The largest seller was Capital Fund Management (CFM), exiting entirely with an estimated $4.46M sold.
- 182 institutional investors held Altimmune (ALT) as of Q4 2024, up from 169 in Q3 2024.
- Funds reported $292M of Altimmune stock for Q4 2024, up 20% quarter-over-quarter.
- 38 funds opened new Altimmune positions in Q4 2024 and 23 closed out, a net change of +15 holders.
- The largest Altimmune buyer in Q4 2024 was Ameriprise, an estimated $10.5M added.
- The largest Altimmune seller in Q4 2024 was Capital Fund Management (CFM), an estimated $4.46M sold.
Based on aggregated 13F filings for Q4 2024.